Susquehanna International Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Susquehanna International Group’s Portfolio YMAB Stock Details YMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-27,000	Closed	-$439K	–	13392
2024 Q1	$439K	Buy	+27,000	New	+$364K	﹤0.01%	8829
2021 Q4	–	Sell	-12,200	Closed	-$348K	–	14036
2021 Q3	$348K	Buy	+12,200	New	+$384K	﹤0.01%	10263
2021 Q2	–	Sell	-16,000	Closed	-$484K	–	13372
2021 Q1	$484K	Buy	+16,000	New	+$656K	﹤0.01%	9548

Other funds holding YMAB

BIG

Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Susquehanna International Group's YMAB Position: Q3 2025 in Review

Susquehanna International Group sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 51,090 shares — an estimated $230K sold.

Susquehanna International Group first reported a position in YMAB in Q3 2019 and held it in 21 quarters. The position peaked at $759K in Q3 2021. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

Susquehanna International Group reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
Susquehanna International Group sold 51,090 Y-mAbs Therapeutics shares in Q3 2025, an estimated $230K.
Susquehanna International Group first reported a position in Y-mAbs Therapeutics in Q3 2019 and held it in 21 quarters.
Susquehanna International Group's Y-mAbs Therapeutics position peaked at $759K in Q3 2021.
2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Susquehanna International Group's 13F filing for Q3 2025, filed 14 Nov 2025.